Smith & Nephew SNATS, Inc. $SNN Stock Position Lifted by Boston Partners

Key Points

• Boston Partners increased its stake in Smith & Nephew SNATS by 44.8% during Q1, owning 129,893 shares valued at approximately $3.7 million.
• Smith & Nephew SNATS stock is currently down 1.1% and has a market cap of $15.85 billion, with a 52-week price range between $23.69 and $36.84.
• The company recently declared a semi-annual dividend of $0.285 per share, set to be paid on November 7th, representing a dividend yield of 210.0%.

Boston Partners grew its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 44.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 129,893 shares of the medical equipment provider's stock after purchasing an additional 40,211 shares during the period. Boston Partners' holdings in Smith & Nephew SNATS were worth $3,685,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bessemer Group Inc. boosted its position in Smith & Nephew SNATS by 3,471.4% during the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,701 shares during the period. Sequoia Financial Advisors LLC bought a new stake in Smith & Nephew SNATS in the 1st quarter valued at about $211,000. GAMMA Investing LLC lifted its position in Smith & Nephew SNATS by 22.4% in the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock valued at $103,000 after purchasing an additional 666 shares during the last quarter. Townsquare Capital LLC lifted its position in Smith & Nephew SNATS by 19.0% in the 4th quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock valued at $432,000 after purchasing an additional 2,798 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Smith & Nephew SNATS in the fourth quarter valued at approximately $435,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SNN shares. Hsbc Global Res lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group raised their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research note on Monday. Finally, HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $36.00.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock traded up $0.5450 during trading hours on Wednesday, hitting $37.4250. 542,114 shares of the company traded hands, compared to its average volume of 894,940. The firm has a market cap of $16.39 billion, a P/E ratio of 17.33, a P/E/G ratio of 1.00 and a beta of 0.68. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The firm's 50-day simple moving average is $31.51 and its two-hundred day simple moving average is $29.00. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $37.58.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's payout ratio is currently 26.39%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.